NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of Avalanche Biotechnologies, Inc. (NASDAQ:AAVL) resulting from allegations that Avalanche Biotechnologies may have issued materially misleading business information to the investing public.
On June 15, 2015, Avalanche Biotechnologies announced results from its Phase IIa trial of its gene therapy treatment for wet age-related macular degeneration and said that the study was not designed to show significant statistical differences between the active and control groups. On this news, shares of Avalanche Biotechnologies fell $21.83 per share or over 56% to close at $17.05 per share.
The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Avalanche Biotechnologies investors. If you purchased shares of Avalanche Biotechnologies on or before June 15, 2015, please visit the firm’s website at http://rosenlegal.com/cases-642.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.